Nectar Lifesciences Ltd Share Price & Stock Analysis

Nectar Lifesciences Ltd (NSE: NECLIFE, BSE: 532649) is a Chandigarh-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹201 Cr, it ranks #2,643 by market cap among the 6,197 Indian listed companies on FinBizNet, and #55 of 86 in Medicinal Chemicals and Botanical Products. At ₹10.60 (as of 16 Nov 2026), the share price is 52.7% below its 52-week high of ₹22.40 and 14.0% above its 52-week low of ₹9.30. The share price is down 27.4% over one year and down 6.0% over three months.

Key Metrics

Current Price₹10.60
Market Cap₹201 Cr
NSE SymbolNECLIFE
BSE Code532649
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Medicinal Chemicals and Botanical Products
P/E RatioNot meaningful (loss)
Return on Equity-7.46%
Return on Assets-5.21%
52-Week Range₹9.30 – ₹22.40
1-Year Price Change-27.4%
3-Month Price Change-6.0%
Beta (1Y)0.9
Dividend Yield0.00%
HeadquartersChandigarh
Websitewww.neclife.com

Latest Quarterly Results — Q2 FY27

Revenue₹0 Cr
Net Profit₹3 Cr
Net Margin27200.0%
EPS (Basic)₹0.18
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Nectar Lifesciences Ltd Quarterly Revenue and Profit Trend

Nectar Lifesciences Ltd reported revenue of ₹0 Cr in Q2 FY27, down 99.8% from ₹5 Cr in Q2 FY26 and up 0.0% from ₹0 Cr in Q1 FY27. It posted a net profit of ₹3 Cr for the quarter, against a net loss of ₹176 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹0 Cr (Q4 FY26) to ₹431 Cr (Q4 FY25). The company reported a net loss in 5 of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹0 Cr₹3 Cr27200.0%
Q1 FY27₹0 Cr−₹15 Cr−154000.0%
Q4 FY26₹0 Cr−₹68 Cr—
Q3 FY26₹0 Cr₹14 Cr—
Q2 FY26₹5 Cr−₹176 Cr−3520.2%
Q1 FY26₹281 Cr−₹63 Cr−22.5%
Q4 FY25₹431 Cr−₹130 Cr−30.2%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 51.84% of Nectar Lifesciences Ltd's shares as of Sept 2026, against 44.91% in Dec 2025 (+6.93 percentage points). Delivery averaged 76.1% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Nectar Lifesciences Ltd

Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also provides contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company offers menthol and pearl capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.

Products and Services

1. Pharmaceutical Business-This segment operates as an integrated pharmaceutical company. It manufactures active pharmaceutical ingredients and formulations.

Nectar Lifesciences Ltd vs Peers — Medicinal Chemicals and Botanical Products

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Sun Pharmaceutical Industries Limited₹4,56,425 Cr39.514.72%₹16,199 Cr+11.2%
Laurus Labs Ltd₹1,31,242 Cr145.617.74%₹2,206 Cr+146.8%
Zydus Lifesciences Ltd₹1,19,651 Cr24.118.32%₹7,910 Cr+26.0%
Dr.Reddys Lab₹1,15,464 Cr26.911.52%₹8,698 Cr+14.5%
Cipla Limited₹1,14,712 Cr29.311.74%₹7,404 Cr-7.6%
Mankind Pharma₹1,09,870 Cr5712.45%₹4,338 Cr+16.7%
Aurobindo Pharma Ltd.₹1,05,150 Cr309.93%₹10,263 Cr+59.8%
Lupin Ltd₹92,087 Cr17.326.91%₹7,827 Cr+0.4%
Nectar Lifesciences Ltd₹201 Crn/m-7.46%₹0 Cr-27.4%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Nectar Lifesciences Ltd?

Nectar Lifesciences Ltd is trading at ₹10.60, with a market capitalisation of ₹201 Cr.

Which sector does Nectar Lifesciences Ltd belong to?

Nectar Lifesciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).

What are the key financial ratios of Nectar Lifesciences Ltd?

Nectar Lifesciences Ltd has a return on equity of -7.46%.

What is the stock symbol of Nectar Lifesciences Ltd?

Nectar Lifesciences Ltd is listed on the NSE under the symbol NECLIFE and on the BSE under the scrip code 532649.

How has Nectar Lifesciences Ltd's share price moved over the past year?

Nectar Lifesciences Ltd's share price is down 27.4% over one year and down 6.0% over three months. Its 52-week range is ₹9.30 to ₹22.40.

What were Nectar Lifesciences Ltd's latest quarterly results?

In Q2 FY27, Nectar Lifesciences Ltd reported revenue of ₹0 Cr and net profit of ₹3 Cr, with basic EPS of ₹0.18 (consolidated, parsed from the company's exchange filing).

How have Nectar Lifesciences Ltd's revenue and profit changed over the past year?

Nectar Lifesciences Ltd reported revenue of ₹0 Cr in Q2 FY27, down 99.8% from ₹5 Cr in Q2 FY26 and up 0.0% from ₹0 Cr in Q1 FY27.

What is the promoter holding in Nectar Lifesciences Ltd?

Promoters held 51.84% of Nectar Lifesciences Ltd's shares as of Sept 2026, against 44.91% in Dec 2025 (+6.93 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.